On April 6, Hengrui Medicine issued an announcement stating that its subsidiary Chengdu Shengdi had recently received the "Drug Registration Certificate" for mycophenolate sodium enteric-coated tablets approved and issued by the State Food and Drug Administration.
Mycophenolate Sodium is a hypoxanthine monophosphate dehydrogenase (IMPDH) inhibitor.
It is suitable for combination with cyclosporine and corticosteroids to prevent acute rejection in adult patients receiving allogeneic kidney transplantation.
Mycophenolate sodium enteric-coated tablets were developed by Novartis under the trade name Myfortic.
They were first approved for listing in Switzerland in October 2002, and are currently on the market in the United States, China, the European Union and other countries and regions.
At present, except for Novartis, only Chengdu Shengdi's products have been approved for listing.
Upon inquiry, the global sales of mycophenolic acid tablets in 2019 was approximately US$499.
Up to now, the total R&D expenditure of the Mycophenolate Sodium Enteric-coated Tablets project is approximately RMB 27.